MedPacto EBITDA vs. Total Debt
| 235980 Stock | KRW 4,330 75.00 1.70% |
For MedPacto profitability analysis, we use financial ratios and fundamental drivers that measure the ability of MedPacto to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well MedPacto utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between MedPacto's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of MedPacto over time as well as its relative position and ranking within its peers.
MedPacto |
MedPacto Total Debt vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining MedPacto's current stock value. Our valuation model uses many indicators to compare MedPacto value to that of its competitors to determine the firm's financial worth. MedPacto is rated below average in ebitda category among its peers. It is rated third in total debt category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value MedPacto by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for MedPacto's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.MedPacto Total Debt vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
MedPacto |
| = | (26.36 B) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
MedPacto |
| = | 75.41 B |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
MedPacto Total Debt vs Competition
MedPacto is rated third in total debt category among its peers. Total debt of Biotechnology industry is presently estimated at about 1.45 Trillion. MedPacto holds roughly 75.41 Billion in total debt claiming about 5% of stocks in Biotechnology industry.
MedPacto Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in MedPacto, profitability is also one of the essential criteria for including it into their portfolios because, without profit, MedPacto will eventually generate negative long term returns. The profitability progress is the general direction of MedPacto's change in net profit over the period of time. It can combine multiple indicators of MedPacto, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers MS-1601A that targets TRG1 for cancers and autoimmune diseases and vactosertib for solid tumors. MedPacto is traded on Korean Securities Dealers Automated Quotations in South Korea.
MedPacto Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on MedPacto. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of MedPacto position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the MedPacto's important profitability drivers and their relationship over time.
Use MedPacto in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MedPacto position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MedPacto will appreciate offsetting losses from the drop in the long position's value.MedPacto Pair Trading
MedPacto Pair Trading Analysis
The ability to find closely correlated positions to MedPacto could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MedPacto when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MedPacto - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MedPacto to buy it.
The correlation of MedPacto is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MedPacto moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MedPacto moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MedPacto can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your MedPacto position
In addition to having MedPacto in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Rentals Thematic Idea Now
Rentals
Companies providing rental and leasing services to public and business. The Rentals theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rentals Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in MedPacto Stock
To fully project MedPacto's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of MedPacto at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include MedPacto's income statement, its balance sheet, and the statement of cash flows.